
ODTX Stock Forecast & Price Target
ODTX Analyst Ratings
Bulls say
Odyssey Therapeutics is an innovative company with strong potential in the biopharmaceutical market, backed by their partnership with JNJ and promising pipeline assets. With their focus on targeting multiple cytokines and utilizing advanced technology, they are well-positioned to address the growing demand for effective treatments for autoimmune diseases like lupus and IBD. The company also has a healthy financial standing, evident from their $2.5 million in revenue in 2025 and the expected growth of the market for IBD treatments.
Bears say
Odyssey Therapeutics is a clinical-stage biopharmaceutical company focusing on autoimmune and inflammatory diseases. The limited clinical validation of Odyssey's novel target, SLC15A4, and the risk of failure to meet primary endpoints or below expected efficacy in the company's ongoing studies lead to a negative outlook. Additionally, safety signals could emerge from the studies. However, the company's unique approach using scaffolding targeting instead of kinase inhibition for their lead asset, OD-001, along with its benign safety profile and competitive phase 2a data, gives some confidence in the upcoming combination and monotherapy trials. The company's novel program targeting TNFR2 also shows potential, but the limited validation and competition from similar approaches could hinder its success.
This aggregate rating is based on analysts' research of Odyssey Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
ODTX Analyst Forecast & Price Prediction
Start investing in ODTX
Order type
Buy in
Order amount
Est. shares
0 shares